Merck & Co., Inc. stock (US58933Y1055): Key takeaways after the latest Keytruda and Gardasil updates

Merck & Co., Inc. remains in focus after fresh updates around its cancer drug Keytruda and HPV vaccine Gardasil, while investors watch the pharma heavyweight’s pipeline and patent timeline in a volatile healthcare market.

Merck & Co., Inc. has stayed in the spotlight recently as it reported new study and regulatory developments around its blockbuster cancer therapy Keytruda and its HPV vaccine franchise Gardasil, both central pillars of the US pharma group’s growth story, according to company communications and major business media reports published in the last few weeks, including Reuters as of 04/08/2026 and updates cited by Merck investor news as of 04/25/2026.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck & Co.
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Kenilworth, New Jersey, United States
• Core markets: Global prescription drugs, vaccines, animal health
• Key revenue drivers: Oncology therapies, vaccines, animal health portfolio
• Home exchange/listing venue: New York Stock Exchange (ticker: MRK)
• Trading currency: US dollar (USD)

Merck & Co., Inc.: core business model

Merck & Co., Inc. is one of the largest US-based healthcare companies, with a primary focus on prescription medicines for serious diseases such as cancer, infectious illnesses and cardiometabolic conditions. The group generates the majority of its sales from patented drugs and vaccines, complemented by an animal health division that provides products for livestock and companion animals, according to its annual reporting for 2025 published in February 2026 and summarized by Merck annual report as of 02/22/2026.

The core of Merck’s business model is research-driven: the company invests heavily in R&D to discover new therapies, prove clinical benefit through large-scale trials and then secure approvals from regulators such as the US Food and Drug Administration and the European Medicines Agency. Once approved, these products are commercialized globally, often with premium pricing during the patent-protected period, a strategy that helps fund the next wave of innovation but also exposes the firm to patent expiry risk, as described in the company’s risk disclosures in its latest Form 10-K filed with the US Securities and Exchange Commission and highlighted by SEC filing as of 02/26/2026.

Merck organizes its operations mainly around human health and animal health segments. The human health unit includes oncology, vaccines and various hospital acute care products, while animal health provides vaccines, antiparasitics and other treatments for cattle, swine, poultry and pets. This diversification offers some earnings resilience, yet the group’s earnings profile is increasingly shaped by a handful of high-growth blockbusters such as Keytruda in oncology and Gardasil in vaccines, a trend that investors closely monitor in quarterly updates, according to coverage from Reuters as of 04/25/2026.

Main revenue and product drivers for Merck & Co., Inc.

Keytruda, Merck’s immuno-oncology therapy targeting the PD-1 pathway, has become the company’s single most important product, generating tens of billions of dollars in annual sales in recent years, with the latest full-year 2025 figures released in late April 2026 showing continued double-digit growth, according to Merck earnings release as of 04/25/2026. The drug is approved for multiple cancer indications, including lung, melanoma and certain gastrointestinal and head and neck cancers, and new combinations and earlier-line uses are being explored in ongoing trials.

Gardasil, Merck’s human papillomavirus vaccine franchise, is another key growth driver. The company reported that higher demand in both the United States and international markets supported Gardasil sales in 2025, with continued uptake in prevention programs for cervical and other HPV-related cancers, as detailed in its 2025 results announcement cited by Merck news release as of 04/25/2026. For a large-cap pharma name, the concentration in two franchises is significant, prompting investors to follow each clinical, regulatory or manufacturing update around these products closely.

Beyond these blockbusters, Merck also generates meaningful revenue from hospital acute care, diabetes and cardiovascular therapies, as well as from its animal health segment. In its full-year 2025 update, management highlighted steady growth in animal health driven by demand for companion animal products and vaccines for livestock, which can help cushion volatility in the human health portfolio during patent transitions, according to comments summarized in Fierce Pharma as of 04/26/2026.

Why Merck & Co., Inc. matters for US investors

For US investors, Merck represents one of the core blue-chip names in the healthcare sector, with a long dividend history and a position in major stock indices such as the Dow Jones Industrial Average and the S&P 500. Its shares are widely held by institutional investors, mutual funds and ETFs that seek broad exposure to large-cap US equities, making Merck’s performance relevant not only for stock pickers but also for diversified portfolios, as discussed by market strategists quoted in CNBC as of 04/26/2026.

Merck’s exposure to global healthcare spending trends, aging populations and increased focus on cancer and infectious disease treatments ties its long-term prospects closely to macro and policy developments in the United States. Changes to US drug pricing rules, Medicare negotiations and competition from biosimilars can all influence the company’s profitability profile, a topic that has been repeatedly highlighted in congressional hearings and policy debates covered by The Wall Street Journal as of 03/15/2026.

At the same time, the company’s broad pipeline in oncology, vaccines and cardiometabolic diseases means that positive or negative trial readouts can trigger noticeable share price moves on the New York Stock Exchange. For US-based retail investors, Merck is often seen as a way to gain exposure to innovative cancer therapies and vaccine technologies within a relatively established, dividend-paying large-cap profile, though the actual risk-return balance depends on individual portfolio construction and tolerance for sector-specific volatility, as emphasized by portfolio managers cited in Bloomberg as of 04/27/2026.

Conclusion

Merck & Co., Inc. remains a central player in global pharmaceuticals, with its stock shaped by the ongoing success of Keytruda and Gardasil, the pace of its broader pipeline and policy discussions around US drug pricing. Recent clinical and regulatory updates underscore both the potential and the concentration risk in its oncology and vaccine franchises, while the animal health and other human health products provide diversification. For market participants in the United States and abroad, Merck’s next data readouts, regulatory milestones and guidance updates will likely be key reference points when assessing how the company navigates patent cliffs, competition and a changing healthcare policy landscape, without any single outcome guaranteeing a specific share price direction.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.